Trial record 1 of 72 for:    cholangiocarcinoma | Open Studies | Exclude Unknown | "Cholangiocarcinoma"
Previous Study | Return to List | Next Study

A Phase II Study of Cabozantinib (XL-184) Monotherapy in Patients With Advanced Cholangiocarcinoma After Progression on First or Second Line Systemic Therapy

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2014 by Massachusetts General Hospital
Sponsor:
Collaborator:
Exelixis
Information provided by (Responsible Party):
Goyal, Lipika, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT01954745
First received: September 24, 2013
Last updated: July 8, 2014
Last verified: July 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: February 2021
  Estimated Primary Completion Date: June 2017 (Final data collection date for primary outcome measure)